News Related to Hypoalbuminemia

Related coverage linked through entity extraction aliases.

FDA Approves Pembrolizumab for Platinum-Resistant Ovarian Cancer

Feb 28, 2026

The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).

FDA Approves Pembrolizumab Combinations for Platinum-Resistant Ovarian Cancer

Feb 12, 2026

The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.